Shaanxi Provincial Center for Disease Control and Prevention
14
3
4
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 14 trials
100.0%
+13.5% vs industry average
71%
10 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines
Role: collaborator
Phase I Clinical Trial of PCV24 in Children Aged 2 Months (Minimum 6 Weeks) to 17 Years
Role: collaborator
Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell)
Role: collaborator
Adsorption of Cell-free Diphtheria and Tetanus (Three-component) Combined With Vaccine Phase III Clinical Trial
Role: collaborator
A Clinical Trial of Quadrivalent Influenza Virus Split Vaccine (MDCK Cells) for Individuals Aged 6 Months and Above.
Role: collaborator
Hemodynamic Comparison of Peripheral and Central VA ECMO.
Role: collaborator
Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (Sinopharm BBIBP-CorV) Coadministered With Rabies Vaccine
Role: collaborator
Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Expanded Programme on Immunization Vaccines
Role: collaborator
Evaluation of the Safety and Immunogenicity of Hepatitis A Vaccine
Role: collaborator
Evaluation of Safety and Immunogenicity of Combined Immunization of sIPV, DTaP and HepA
Role: collaborator
To Evaluate the Immunogenicity and Safety of Sequential Immunization Schedules of Sabin IPV and bOPV
Role: collaborator
Clinic Trial to Evaluate the Safety and Immunogenicity of Combined Immunization of sIPV and DTaP
Role: collaborator
Clinical Study on Combined Immune Effect of EV71 Inactivated Vaccine
Role: collaborator
Comparative Immunogenicity Study of Two Hepatitis A Vaccines
Role: collaborator
All 14 trials loaded